# ALCOHOL WITHDRAWAL by Nick Mark MD & Mark Ramzy DO

### BACKGROUND/DEFINITIONS:

Ethanol is the most common drug of abuse in the world, by far the most costly in lives lost and dollars spent. 5% of Americans are heavy drinkers (≥8 drinks/wk for Q or ≥15 drinks/wk for Q) and 50% of heavy drinkers

experience alcohol withdrawal. Despite the frequency, alcohol withdrawal (or AWS) is frequently misdiagnosed (and under-treated) in the ICU. Heavy drinking for as little as 15 days is sufficient to precipitate EtOH W/D.

### PATHOPHYSIOLOGY:

Consumption of large quantities of EtOH leads to constitutive GABAergic signaling and compensatory upregulation of NMDA and other excitatory neurotransmitters. Removal of EtOH & its inhibitor effects leads to overexcitation of neurons. This causes a range of syndromes over hours to days.

## SCORING ALCOHOL WITHDRAWAL SYNDROME (AWS):

Use of a structured tool for assessing severity of AWS can facilitate diagnosis, track severity, and directly trigger treatment. Several exist:

observations + participation

actively being experienced

delirium from other causes

by altered mental status

accuracy by several points

· Determines severity as sx are

· Can't differentiate b/w DTs &

Requires participation, limited

· Variability in scoring can limit

· Scores o – 9 = Absent/minimal ·

Scores 10 - 19 = Mild/moderate ·

Scores ≥ 20 = Severe w/d (high risk

· Validated 10-item tool based on

CIWA-Ar

level, Sx

PAWSS: · Validated 10 item questionnaire divided

into 3 parts combines interview, blood EtOH

 Screening tool used to identify patients at risk for severe withdrawal (Se = 93% & Sp = 99.5%)

Requires pt participation, limited by AMS Score ≥ 4 = HIGH RISK

for moderate to severe withdrawal

VITAL SIGNS

for impeding DTs)

· Developed from CIWA-Ar to cover entire spectrum of withdrawal

· Operationalized 6 objective findings + 5 psych/behavioral symptoms · Max score of 34 (17 for each

of the two sections) · Less reliant on patient's responses • Score o - 5 = Absent tominimal withdrawal

· Score 6 - 9 = Moderate · Score ≥ 20 = Severe

withdrawal

withdrawal

## · LIMITED BY EXCLUSION OF

### CLINICAL MANIFESTATIONS:

Symptoms and clinical syndromes of EtOH W/D very by time after last drink

<6 - 12 Hours

with intact orientation & normal sensorium,

**ALCOHOLIC HALLUCINOSIS** 

with normal vital signs

12 - 24 Hours

Midazolam

Diazepam

Lorazepam

ONE

<24 - 48 Hours

onepagericu.com

@Nickmmark

> 72 Hours



MINOR WITHDRAWAL Symptoms:

tremulousness, anxiety, h/a, diaphoresis, palpitations, N/V, w/ normal mentation

## 6-36 hours

## WITHDRAWAL SEIZURES

- 6-48 hours
- 1-3 usually generalized seizures
- Status epilepticus occurs in 3% High risk of progression to DTs

## 12-48 hrs

visual, auditory, & tactile hallucinations,

## TREATMENT

BZDs & Phenobarbital (PHB) are the commonly used treatments. Neither is superior. The goal is to treat symptoms & prevent life threatening complications (seizures & autonomic instability.)

Remember scene safety: AWS/DTs can be dangerous to staff

## **BENZODIAZEPINES (BZDs)**

 Common 1<sup>st</sup> Line therapy, ↑ frequency of GABA-receptor opening · Symptom triggered therapy is preferable to scheduled (less sedation,

shorter treatment duration; however patients with severe AWS may require frequent re-dosing.

• Lorazepam may accumulate less than diazepam in hepatic dysfunction.

Chlorodiazepoxide may be useful adjunct for patients at high risk for eloping

## **BARBITUATES**

- ↑ duration of GABA-receptor channel opening; also decreases glutamate signaling; can be used as a loading dose or boluses. · Used early as monotherapy; equivalence to benzos in some studies
- · Also used in conjunction with benzos for refractory DTs
- **BZD** APPROACH **PHB** APPROACH

# WORKUP

## Labs: CBC, BMP, Mg, Phos, LFTs, EtOH level, TSH

Consider toxic alcohol panel **HEAD CT:** 

Helps differentiate alternative causes

EEG:

For new onset seizure & status epilepticus May see ↓ amplitude of theta/delta waves

### **DDx to Consider** - Hypoglycemia

- Serotonin Syndrome
- Hyponatremia
- Thyrotoxicosis - Head Injury / ICH
- Other intoxications
- Hepatic Encephalopathy

## **NUTRITION & FLUIDS**

Thiamine: cofactor in glucose metabolism

Consider 100 mg IV or IM prophylaxis (avoid giving PO)


- Concern for Wernicke's Encephalopathy: 500mg IV/IM q8h

 earlier initiation, <u>faster the recovery</u> Folate: Deficiency causes megaloblastic anemia

· Consider 1 mg q24 hours Electrolytes: Hypokalemia common & requires repletion

- Hypomagnesemia & Hypophosphatemia may also be seen

- Fluids: Typically high insensible losses; consider replacement



DELIRIUM TREMENS 48-96 hrs (rarely up to 7 days)

Fluctuating cognition &

attention, altered sensorium (hallucinations)

Autonomic instability (low grade fever, tachycardia,

hypertension, diaphoresis)

Onset Duration Route (min) (hrs)

Dose (mg) 2 - 41 - 5<2 IM, IV 10 - 20PO. PR. 1 - 3<1 q5-10 min IM, IV 2 - 45 - 106 - 8PO, IM, IV q15-30 min

50 - 100Chlordiazepoxide > 30 24 - 48q60 min

PHENOBARBITAL (PHB)

## · Dosing: 130 – 260 mg IV g 15-20 min until symptoms controlled

Onset of action: 5 minutes, peaks at 15 – 30 minutes Infusion: 10-15 mg/kg IV

Duration: 10-12 hrs (elimination half life is days) longer in cirrhosis

· In patients w/o cirrhosis, consider a taper 1 mg/kg PO once

Consider PHB Monotherapy if PHB IV load

· Definite AWS; history of DTs or at high risk for delirium

(e.g. PAWSS >4), prior ICU admission for AWS

· No other neurological problems (hepatic encephalopathy)

· Not on meds that interact with phenobarb (HIV meds) · Has not received high doses of BZDs already

· No history of AIP or on chronic PHB already

reduces BZD dose, may reduce need for intubation, & may ↑ or ↓ hospital LOS. Monitor for bradycardia. CLONIDINE 0.1 - 0.2 mg PO: Used to reduce

**DEXMETOMIDINE infusion:** Possible BZD adjunct

autonomic symptoms of withdrawal. Max 1.2 mg/day.

HALOPERIDOL 2.5 - 5 mg IV/IM q 4 hrs: Used for persistent agitation. Does not replace BZD or PHB. Use

with caution as can lower seizure threshold & impair heat dissipation. Check ECG prior and monitor QTc. BACLOFEN & KETAMINE - theoretic benefits;

limited literature to support their use. Avoid. \*If using higher bolus doses: monitor total dose & check PHB levels